You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Evaluation of a mobile app-based video Directly Observed Therapy (video DOT) intervention for medication adherence in pediatric heart transplant patients

    SBC: EMOCHA MOBILE HEALTH INC.            Topic: NHLBI

    Few interventions have proven to be successful in promoting medication adherence and impacting short- and long-term posttransplant outcomes in adolescent heart transplant (HT) recipients. Improving adherence is a persistent challenge with youth experiencing chronic health conditions, especially among adolescent transplant recipients. Adolescent organ transplant recipients experience unique challen ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)

    SBC: Rise Therapeutics, LLC            Topic: NIAID

    PROJECT SUMMARY Acute respiratory distress syndrome (ARDS) is a severe life-threatening complication that can be caused by viral infection. The disease is characterized by cytokine-driven hyperinflammation and leukocytes count changes. The innate immune response has been linked to ARDS immunopathogenesis. In this regard, neutrophils have been highlighted as essential effector cells in the developm ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias

    SBC: Path Biotech, LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBC: NUVOX PHARMA, L.L.C.            Topic: NINDS

    ABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Artificial Intelligent Augmented Reality Police E-Trainer for Culturally Competent De-Escalation and Non-Lethal Force Police Training to Eradicate Police Violence Against Black Males

    SBC: JUXTOPIA LLC            Topic: NIMHD

    PROJECT SUMMARY/ABSTRACTPolice violence against black males, in the United States (U.S.), is a public health disparity [37]. Physical andpsychological violence that is structurally mediated by systems of law enforcement, results in deaths, injuries,trauma, and stress that disproportionately affect blacks in the U.S. According to a 2019 study, published in theProceedings of the National Academy of ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced Prediction of Emerging Respiratory Decline with the Linshom Continuous Predictive Respiratory Sensor (CPRS)

    SBC: LINSHOM MEDICAL INC            Topic: NHLBI

    Abstract: This Fast-track SBIR application will fund and enable a new approach to respiratory monitoring, continuous predictive respiratory monitoring (CPRM), that stands to reduce morbidity and mortality due to respiratory compromise, while reducing health care system costs. Current devices and systems (human and machine) for respiratory monitoring are responsive by sounding a warning alarm when ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis

    SBC: AAVOGEN INC            Topic: NIA

    PROJECT SUMMARY. Gene therapy offers hope to patients with sporadic inclusion body myositis (IBM). This chronic rare disease exclusively affects older adults and results from inflammation rather than genetic mutations. Thus, it cannot be treated with gene replacement or gene editing approaches yet durable solutions like gene therapies are needed to address the progressive muscle degeneration. Such ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Extended-Release Formulation of Mas Receptor Agonists as Novel Therapeutics for Treating Cognitive Impairment in Patients at-risk forAlzheimer's Disease-Related Dementias and Vascular Dementia

    SBC: Proneurogen, Inc            Topic: NIA

    Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050. Several studies have shown that VCID and conversion to ADRD are strongly correlated with vascular disease, inflammation an ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government